Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-011: pembrolizumab + lenvatinib versus pembrolizumab + placebo as first-line treatment for advanced or metastatic urothelial carcinoma in platinum-ineligible patients
MOH_2019-04-08_006078Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transitional cell carcinoma (TCC) comparing Keytruda + Lenvima with Keytruda + placebo (2 arms). Primary endpoint: Primary endpoint not reported in registry entry. Started Mar 2019; status: active, not recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on MOH_2019-04-08_006078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-04-08_006078.